GCG and obesity due to melanocortin 4 receptor deficiency: GLP-1 RAs hold a prominent position in the diabetes and obesity treatment paradigm due to their multiple advantages, such as robust glycemic control, relatively low risk of hypoglycemia, favorable adherence, and cardiovascular benefits.